RxDoctor Payments Data

John Ramirez, MD

Cardiovascular Disease · Tampa, FLNPI 1649266222

Payments from drug & device makers

$2,398in general payments, 2019–2025

Across 42 payments — averaging $57.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • United Therapeutics Corporation$242
  • Inspire Medical Systems, Inc.$132
  • Pfizer$90
  • AstraZeneca$50
  • Alnylam Pharmaceuticals Inc.$48
  • plus $319 from 13 others

What the payments were for

  • Travel & lodging$1,27653%
  • Food & beverage$1,06644%
  • Education$562%

General payments by program year

19
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,398 in reported general payments places this provider in the 40th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$196,277
Medicare patients
624
Services billed
2,455

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban402$471,679
XareltoRivaroxaban205$236,688
EntrestoSacubitril/Valsartan151$213,912
JardianceEmpagliflozin86$112,159
Repatha SureclickEvolocumab96$95,610
FarxigaDapagliflozin Propanediol54$65,384
NexlizetBempedoic Acid/Ezetimibe55$39,432
Praluent PenAlirocumab16$19,151
VascepaIcosapent Ethyl36$19,059
MultaqDronedarone Hcl15$18,208
JanuviaSitagliptin Phosphate11$12,935
EdarbiAzilsartan Medoxomil24$5,759
Amlodipine Besylate850$5,684
Atorvastatin Calcium566$5,569
Losartan Potassium560$5,398

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$90$471,679402 claims
Johnson & JohnsonXarelto$23$236,688205 claims
Boehringer IngelheimJardiance$40$112,15986 claims
AstraZenecaFarxiga$50$65,38454 claims
Sanofi-aventis U.S. LLCMultaq$20$18,20815 claims
Arbor Pharmaceuticals, Inc.Edarbi$16$5,75924 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Tampa

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →